Epstein Secrets

place statins," says Schliefer, the Regeneron CEO. Most people who have muscle problems from statins do not have those elevated muscle enzymes, says Nissen, the Cleveland Clinic cardiologist, who is conducting a clinical trial Amgen and Pfizer, which is also developing a similar cholesterol drug. He sa

ing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI's pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

at patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven HOUSE_OVERSIGHT_025888 --- PAGE BREAK --- Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical offi

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical offi

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for